Inhibition of topoisomerase IIα: Novel function of wedelolactone

Cancer Letters

Volumn 303, Issue 1, 2011, Pages 29-38

  Benes, Petr ^a   Knopfova, Lucia ^a   Trcka, Filip ^a   Nemajerova, Alice ^a   Pinheiro, Diana ^a   Soucek, Karel ^b   Fojta, Miroslav ^b   Smarda, Jan ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Apoptosis; DNA damage; Proliferation; Topoisomerase; Wedelolactone

Indexed keywords

ANDROGEN RECEPTOR; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOPOISOMERASE 2 ALPHA; UNCLASSIFIED DRUG; WEDELOLACTONE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; SIGNAL TRANSDUCTION; TOPOISOMERASE INHIBITORS;

EID: 79951852253     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.002     Document Type: Article

References (52)

1. Govindachari T.R., Nagurajan K., Pai B.R. Chemical examination of Wedelia calendulacea. Part I. Structure of wedelolactone. Chem. Soc. 1956, 629-632.
2. Mors W.B., do Nascimento M.C., Parente J.P., da Silva M.H., Melo P.A., Suarez-Kurtz G. Neutralization of lethal and myotoxic activities of South American rattlesnake venom by extracts and constituents of the plant Eclipta prostrata (Asteraceae). Toxicon 1989, 27:1003-1009.
3. Wagner H., Geyer B., Kiso Y., Hikino H., Rao G.S. Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulacea. Planta Med. 1986, 52:370-374.
4. Kobori M., Yang Z., Gong D., Heissmeyer V., Zhu H., Jung Y.K., Gakidis M.A., Rao A., Sekine T., Ikegami F., Yuan C., Yuan J. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 2004, 11:123-130.
5. Diogo L.C., Fernandes R.S., Marcussi S., Menaldo D.L., Roberto P.G., Matrangulo P.V., Pereira P.S., França S.C., Giuliatti S., Soares A.M., Lourenço M.V. Inhibition of snake venoms and phospholipases A(2) by extracts from native and genetically modified Eclipta alba: isolation of active coumestans. Basic Clin. Pharmacol. Toxicol. 2009, 104:293-299.
6. Kaushik-Basu N., Bopda-Waffo A., Talele T.T., Basu A., Costa P.R., da Silva A.J., Sarafianos S.G., Noël F. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res. 2008, 36:1482-1496.
7. Pôças E.S., Lopes D.V., da Silva A.J., Pimenta P.H., Leitão F.B., Netto C.D., Buarque C.D., Brito F.V., Costa P.R., Noël F Structure-activity relationship of wedelolactone analogues: structural requirements for inhibition of Na+, K+-ATPase and binding to the central benzodiazepine receptor. Bioorg. Med. Chem. 2006, 14:7962-7966.
8. Idris A.I., Libouban H., Nyangoga H., Landao-Bassonga E., Chappard D., Ralston S.H. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol. Cancer Ther. 2009, 8:2339-2347.
9. Vender J.R., Laird M.D., Dhandapani K.M. Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells. Neurosurgery 2008, 62:1122-1127.
10. Lin F.M., Chen L.R., Lin E.H., Ke F.C., Chen H.Y., Tsai M.J., Hsiao P.W. Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis 2007, 28:2521-2529.
11. Tsai C.H., Lin F.M., Yang Y.C., Lee M.T., Cha T.L., Wu G.J., Hsieh S.C., Hsiao P.W. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin. Cancer Res. 2009, 15:5435-5444.
12. Mitchell J.H., Duthie S.J., Collins A.R. Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr. Cancer. 2000, 38:223-228.
13. Javid S.H., Moran A.E., Carothers A.M., Redston M., Bertagnolli M.M. Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. Carcinogenesis 2005, 26:587-595.
14. Domon O.E., McGarrity L.J., Bishop M., Yoshioka M., Chen J.J., Morris S.M. Evaluation of the genotoxicity of the phytoestrogen, coumestrol, in AHH-1 TK() human lymphoblastoid cells. Mutat. Res. 2001, 474:129-137.
15. Kulling S.E., Metzler M., micronuclei Induction of DNA strand breaks and HPRT mutations in cultured Chinese hamster V79 cells by the phytoestrogen coumoestrol. Food Chem. Toxicol. 1997, 35:605-613.
16. Horvath V., Soucek K., Svihalkova-Sindlerova L., Vondracek J., Blanarova O., Hofmanova J., Sova P., Kozubik A. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Invest. New Drugs 2007, 25:435-443.
17. Ondrouskova E., Slovackova J., Pelkova V., Prochazkova J., Soucek K., Benes P., Smarda J. Heavy metals induce phosphorylation of the Bcl-2 protein by Jun N-terminal kinase. Biol. Chem. 2009, 390:49-58.
18. Benes P., Maceckova V., Zdrahal Z., Konecna H., Zahradnickova E., Muzik J., Smarda J. Role of vimentin in regulation of monocyte/macrophage differentiation. Differentiation 2006, 74:265-276.
19. Pommier Y., Covey J.M., Kerrigan D., Markovits J., Pham R. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res. 1987, 15:6713-6731.
20. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell. Res. 1988, 175:184-191.
21. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993, 53:3976-3985.
22. Larsen A.K., Escargueil A.E., Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. 2003, 99:167-181.
23. Gong Y., Firestone G.L., Bjeldanes L.F. 3,3'-Diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells. Mol. Pharmacol. 2006, 69:1320-1327.
24. Yang S.Y., Jia X.Z., Feng L.Y., Li S.Y., An G.S., Ni J.H., Jia H.T. Inhibition of topoisomerase II by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells. Biochem. Pharmacol. 2009, 77:433-443.
25. Woynarowski J.M., Sigmund R.D., Beerman T.A. DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cells. Biochemistry 1989, 28:3850-3855.
26. Pivonkova H., Sebest P., Pecinka P., Ticha O., Nemcova K., Brazdova M., Jagelska E.B., Brazda V., Fojta M. Selective binding of tumor suppressor p53 protein to topologically constrained DNA: modulation by intercalative drugs. Biochem. Biophys. Res. Commun 2010, 393:894-899.
27. Zheng J.P., Zhang Y., Edvinsson L., Hjalt T., Xu C.B. NF-kappaB signaling mediates vascular smooth muscle endothelin type B receptor expression in resistance arteries. Eur. J. Pharmacol. 2010, 637:148-154.
28. Mohan S., Konopinski R., Yan B., Centonze V.E., Natarajan M. High glucose-induced IKK-Hsp-90 interaction contributes to endothelial dysfunction. Am. J. Physiol. Cell. Physiol. 2009, 296:182-192.
29. Malara N., Focà D., Casadonte F., Sesto M.F., Macrina L., Santoro L., Scaramuzzino M., Terracciano R., Savino R. Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells. Cell Cycle 2008, 7:3235-3245.
30. Tanabe K., Nishimura K., Dohi S., Kozawa O. Mechanisms of interleukin-1beta-induced GDNF release from rat glioma cells. Brain Res. 2009, 1274:11-20.
31. Tanabe K., Matsushima-Nishiwaki R., Yamaguchi S., Iida H., Dohi S., Kozawa O. Mechanisms of tumor necrosis factor-alpha-induced interleukin-6 synthesis in glioma cells. J. Neuroinflammation 2010, 7:16-24.
32. Mitchell S., Abel P., Madaan S., Jeffs J., Chaudhary K., Stamp G., Lalani N. Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia 2002, 4:9-18.
33. Hall R.E., Birrell S.N., Tilley W.D., Sutherland R.L. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur. J. Cancer 1994, 30A:484-490.
34. Singer C.F., Kronsteiner N., Hudelist G., Marton E., Walter I., Kubista M., Czerwenka K., Schreiber M., Seifert M., Kubista E. Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin. Cancer Res. 2003, 9:4877-4883.
35. Lin H.Y., Sun M., Lin C., Tang H.Y., London D., Shih A., Davis F.B., Davis P.J. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J. Steroid Biochem. Mol. Biol. 2009, 113:182-188.
36. Nelson S.M., Ferguson L.R., Denny W.A. Non-covalent ligand/DNA interactions: minor groove binding agents. Mutat. Res. 2007, 623:24-40.
37. Anderson H.J., Roberge M. DNA topoisomerase II: a review of its involvement in chromosome structure, DNA replication, transcription and mitosis. Cell. Biol. Int. Rep. 1992, 16:717-724.
38. Luo K., Yuan J., Chen J., Lou Z. Topoisomerase IIalpha controls the decatenation checkpoint. Nat. Cell. Biol. 2009, 11:204-210.
39. Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., Shieh S.Y., Taya Y., Prives C., Abraham R.T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999, 13:152-157.
40. Ward I.M., Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J. Biol. Chem. 2001, 276:47759-47762.
41. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., Luo G., Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000, 14:1448-1459.
42. Fernandez-Capetillo O., Lee A., Nussenzweig M., Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair 2004, 3:959-967.
43. Kurose A., Tanaka T., Huang X., Traganos F., Darzynkiewicz Z. Synchronization in the cell cycle by inhibitors of DNA replication induces histone H2AX phosphorylation: an indication of DNA damage. Cell Prolif. 2006, 39:231-240.
44. Gagou M.E., Zuazua-Villar P., Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol. Biol. Cell. 2010, 21:739-752.
45. Ewald B., Sampath D., Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol. Cancer Ther. 2007, 6:1239-1248.
46. Marti T.M., Hefner E., Feeney L., Natale V., Cleaver J.E. H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. Proc. Natl. Acad. Sci. USA 2006, 103:9891-9896.
47. Tuduri S., Crabbe L., Tourrière H., Coquelle A., Pasero P. Does interference between replication and transcription contribute to genomic instability in cancer cells?. Cell Cycle 2010, 9:1886-1892.
48. Szilard R.K., Jacques P.E., Laramée L., Cheng B., Galicia S., Bataille A.R., Yeung M., Mendez M., Bergeron M., Robert F., Durocher D. Systematic identification of fragile sites via genome-wide location analysis of gamma-H2AX. Nat. Struct. Mol. Biol. 2010, 17:299-305.
49. Guo N., Faller D.V., Vaziri C. Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive. Cell Growth Differ. 2002, 13:77-86.
50. Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., Giaccia A.J. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 2002, 22:1834-1843.
51. Demidova A.R., Aau M.Y., Zhuang L., Yu Q. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control. J. Biol. Chem. 2009, 284:4132-4139.
52. Hurley P.J., Bunz F. ATM and ATR: components of an integrated circuit. Cell Cycle 2007, 15:414-417.